联合免疫,安全可行——评区域MSLN CAR-T细胞联合抗PD-1药物在治疗恶性胸膜疾病患者中的应用  

Safety and Feasibility:Evaluation of the Application of Regional MSLN CAR⁃T⁃Cell Therapy in Patients With Malignant Pleural Disease,in Combination With the Anti⁃PD⁃1 Agent Pembrolizumab

作　　者：汪阿影 吕镗烽 WANG A-ying;LV Tang-feng(Department of Respiratory Medicine,Jinling Hospital,Nanjing University School of Medicine,Nanjing 210002,China)

机构地区：[1]南京大学医学院附属金陵医院呼吸与危重症医学科,南京210002

出　　处：《循证医学》2023年第5期273-276,共4页The Journal of Evidence-Based Medicine

摘　　要：1文献来源Adusumilli PS,Zauderer MG,Rivière I,et al.A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease,in combination with the anti-PD-1 agent pembrolizumab[J].Cancer Discov,2021,11(11):2748-2763.2证据水平1b。

关 键 词：恶性胸膜疾病 CAR⁃T细胞 抗PD⁃1药物 区域治疗 

分 类 号：R734.3[医药卫生—肿瘤]